{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:15:38Z","timestamp":1784297738399,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001127","name":"Genentech Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aim<\/jats:title><jats:p>The objective of this retrospective, observational, noninterventional cohort study was to investigate prognostic factors of overall survival (OS) in patients with advanced non\u2010small cell lung cancer (aNSCLC) and to develop a novel prognostic model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 4049 patients with aNSCLC diagnosed between January 2011 and February 2020 who received atezolizumab, nivolumab, or pembrolizumab as second\u2010line monotherapy were selected from a real\u2010world deidentified database to build the cohort. Patients could not have received first\u2010line treatment with clinical study drug(s) nor immune checkpoint inhibitors including anti\u2010programmed cell death 1 (PD\u20101)\/programmed death\u2010ligand 1 (PD\u2010L1), and anti\u2010cytotoxic T\u2010lymphocyte\u2010associated protein 4 therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients had a median age of 69\u2009years; 45% were female, 75% White, 70% had stage IV at initial diagnosis, and 70% had nonsquamous histology. A Cox proportional hazards model with lasso regularization was used to build a prognostic model for OS using 18 baseline demographic and clinical factors based on the real\u2010world data cohort. The risk\u2010increasing prognostic factors were abnormally low albumin and chloride levels, Eastern Cooperative Oncology Group performance status score\u2009\u2265\u20092, and abnormally high levels of alkaline phosphatase and white blood cells. The risk\u2010decreasing prognostic factors were PD\u2010L1 positivity, longer time from advanced diagnosis to start of first\u2010line therapy, and higher systolic blood pressure. The performance of the model was validated using data from the OAK trial, and the c\u2010index for the OAK trial validation cohort was 0.65 and 0.67 for the real\u2010world data cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Based on baseline demographic and clinical factors from a real\u2010world setting, this prognostic model was developed to discriminate the risk of death in patients with aNSCLC treated with checkpoint inhibitors as second\u2010line monotherapy, and it performed well in the real\u2010world data and clinical trial cohorts.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1578","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T06:23:08Z","timestamp":1643091788000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real\u2010world data prognostic model of overall survival in patients with advanced <scp>NSCLC<\/scp> receiving anti\u2010<scp>PD<\/scp>\u20101\/<scp>PD\u2010L1<\/scp> immune checkpoint inhibitors as second\u2010line monotherapy"],"prefix":"10.1002","volume":"5","author":[{"given":"Cristina","family":"Julian","sequence":"first","affiliation":[{"name":"Genentech, Inc  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson J. M.","family":"Machado","sequence":"additional","affiliation":[{"name":"Roche Products  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Girish","sequence":"additional","affiliation":[{"name":"Genentech, Inc  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chanu","sequence":"additional","affiliation":[{"name":"Genentech\/Roche  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Heinzmann","sequence":"additional","affiliation":[{"name":"F Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Harbron","sequence":"additional","affiliation":[{"name":"Roche Products  Welwyn Garden City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda","family":"Gershon","sequence":"additional","affiliation":[{"name":"Genentech, Inc  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Genentech, Inc  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zou","sequence":"additional","affiliation":[{"name":"Genentech, Inc  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Quarmby","sequence":"additional","affiliation":[{"name":"Genentech, Inc  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Genentech, Inc  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachi","family":"Chen","sequence":"additional","affiliation":[{"name":"Genentech, Inc  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"American Cancer Society.Cancer facts & figures2020. Accessed April 5 2021.https:\/\/www.cancer.org\/content\/dam\/cancer\u2010org\/research\/cancer\u2010facts\u2010and\u2010statistics\/annual\u2010cancer\u2010facts\u2010and\u2010figures\/2020\/cancer\u2010facts\u2010and\u2010figures\u20102020.pdf"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30958-8"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)01281\u20107"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)32517\u2010X"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.002"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.013"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","unstructured":"MaX LongL MoonS AdamsonBJS BaxiSS.Comparison of population characteristics in real\u2010world clinical oncology databases in the US: flatiron health SEER and NPCR.medRxiv. Accessed April 5 2020.https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.16.20037143v2.full-text.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"e_1_2_10_12_1","unstructured":"BirnbaumB NussbaumN Seidl\u2010RathkopfK et al.2001Model\u2010assisted cohort selection with bias analysis for generating large\u2010scale cohorts from the EHR for oncology research. ArXiv:2001.09765. Accessed April 5 2020.https:\/\/arxiv.org\/abs\/2001.09765"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.006911"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094\u2010017\u20101829\u20105"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.04.007"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12030"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v039.i05"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780030207"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.08.09"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000226"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.101497"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4209"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114471"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475\u20102891\u20109\u201069"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28995"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31816de2b8"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183835"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2015.16.14.5971"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000001196"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1578","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1578","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:16:58Z","timestamp":1692616618000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/cnr2.1578"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1578","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"2021-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1578"}}